Author

Yanina Negievich

Observed name: Y. Negievich

Institution: Adc Therapeutics (Switzerland)

Observed institution: Adc Therapeutics (Switzerland)

OpenAlex ID: A5014665349

S201: Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-label, Multicenter, Phase 2 Study of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (r/r Chl)

2022 · C. Carlo-Stella, S. Ansell, et al. · HemaSphere · 13

Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study

2025 · Alex F. Herrera, Stephen M. Ansell, et al. · Blood Advances · 10

Camidanlumab Tesirine Efficacy and Safety in an Open‐label, Multicenter, Phase 2 Study of Patients (pts) With Relapsed or Refractory Classical Hodgkin Lymphoma (r/r Chl)

2021 · P. L. Zinzani, C. Carlo‐Stella, et al. · Hematological Oncology · 4

Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

2022 · Alex F. Herrera, Stephen M. Ansell, et al. · Blood · 1

HL-339 Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

2022 · Carmelo Carlo-Stella, Stephen Ansell, et al. · Clinical Lymphoma Myeloma & Leukemia

Poster: HL-339 Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

2022 · Carmelo Carlo-Stella, Stephen Ansell, et al. · Clinical Lymphoma Myeloma & Leukemia

Oral Abstract: HL-339 Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

2022 · Carmelo Carlo-Stella, Stephen Ansell, et al. · Clinical Lymphoma Myeloma & Leukemia

Works count: 7

Citation count: 28

H-index: 3

I10-index: 2